Vinge is advising Investor AB in connection with Swedish Orphan Biovitrum AB’s (SOBI) rights issue for a total of approximately SEK 600 million subject to pre-emption rights of the existing shareholders. SOBI is listed on NASDAQ OMX Stockholm. Investor AB and Bo Jesper Hansen (SOBI’s chairman) have undertaken to subscribe for their share of the rights issue and the issue has been underwritten by Carnegie and Handelsbanken. As a consequence thereof, Investor has obtained the requisite dispensation from the Swedish Securities Council.
Vinge’s team advising Investor consists of Olle Sandersson, Pontus Enquist and Jesper Schönbeck.